Gracell: Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma

 

• Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting

• 100% (19/19) patients achieved minimal residual disease negative stringent complete response (MRD- sCR)

https://www.biospace.com/article/releases/gracell-biotechnologies-reports-updated-clinical-data-for-fastcar-t-gc012f-for-high-risk-newly-diagnosed-multiple-myeloma-demonstrating-100-percent-stringent-complete-response-rate/